Predicting spread risk in pheochromocytoma and paraganglioma
Part of Cancer clinical trials.
This study looks at past patient data to find patterns that might predict whether a pheochromocytoma or paraganglioma (rare tumors of the adrenal glands or nerve tissue) will spread. It aims to create a tool to help doctors estimate risk and plan treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a pheochromocytoma or paraganglioma (or a genetic variant that increases risk for these tumors).
- Your diagnosis must have been made in Denmark since 1996.
- You must have tumor tissue or blood samples stored in a biobank for the study to use.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
This study looks at how the immune system responds to rare adrenal or nerve-related tumors (pheochromocytoma and paraganglioma). Researchers want to understand the tumor's environment, which may help improve future treatments.
This study looks at genetic (DNA) changes in people with pheochromocytoma or paraganglioma and related conditions. It may help clarify why these conditions happen and how they run in families.
This study helps doctors better understand and diagnose pheochromocytoma and paraganglioma—rare tumors that release stress hormones and cause high blood pressure and other symptoms. Researchers will study your medical history, blood and urine tests, imaging scans, and genetic information to improve how these conditions are found and understood.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
This study aims to find genetic causes of neuroendocrine tumors in Mexican patients. By understanding your DNA, researchers hope to improve diagnosis and treatment for people with these rare conditions.
Hear when a new Paraganglioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.